Everything below concerns heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-27. Numbers and descriptions here follow the published literature rather than marketing material.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | ACTH(4-7) analogue |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Free N terminus, unmodified side chains |
| Molecular weight | 813.9 Da | Free base; salt forms differ |
| Appearance | White to off-white powder | Lyophilised solid |
| Solubility | Freely soluble in water | Hydrophilic; polar solvents preferred |
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Although life is very sparse at these depths, black smokers are the centers of entire ecosystems. Sunlight is nonexistent, so many organisms, such as archaea and extremophiles, convert the heat, methane, and sulfur compounds provided by black smokers into energy through a process called chemosynthesis. More complex life forms, such as clams and tubeworms, feed on these organisms. The organisms at the base of the food chain also deposit minerals into the base of the black smoker, therefore completing the life cycle. A species of phototrophic bacterium has been found living near a black smoker off the coast of Mexico at a depth of 2,500 m (8,200 ft). No sunlight penetrates that far into the waters. Instead, the bacteria, part of the Chlorobiaceae family, use the faint glow from the black smoker for photosynthesis. This is the first organism discovered in nature to exclusively use a light other than sunlight for photosynthesis. New and unusual species are constantly being discovered in the neighborhood of black smokers. The Pompeii worm Alvinella pompejana, which is capable of withstanding temperatures up to 80 °C (176 °F), was found in the 1980s, and the scaly-foot gastropod (Chrysomallon squamiferum) was first found in 2001 during an expedition to the Indian Ocean's Kairei hydrothermal vent field. The latter uses iron sulfides (pyrite and greigite) for the structure of its dermal sclerites (hardened body parts), instead of calcium carbonate.
Bombesin-like peptides comprise a large family of peptides which were initially isolated from amphibian skin, where they stimulate smooth muscle contraction. They were later found to be widely distributed in mammalian neural and endocrine cells. The amphibian peptides which belong to this family are currently classified into three subfamilies; the Bombesin group, which includes bombesin and alytesin; the Ranatensin group, which includes ranatensins, litorin, and Rohdei litorin; and the Phyllolitorin group, which includes Leu(8)- and Phe(8)-phyllolitorins. In mammals and birds two categories of bombesin-like peptides are known, gastrin-releasing peptide (GRP), which stimulates the release of gastrin as well as other gastrointestinal hormones, and neuromedin B (NMB), a neuropeptide whose function is not yet clear. Bombesin-like peptides, like many other active peptides, are synthesized as larger protein precursors that are enzymatically converted to their mature forms. The final peptides are eight to fourteen residues long.
Before the modern medical era, the primary means for studying the internal structures of the body were dissection of the dead and inspection, palpation, and auscultation of the living. The advent of microscopy opened up an understanding of the building blocks that constituted living tissues. Technical advances in the development of achromatic lenses increased the resolving power of the microscope, and around 1839, Matthias Jakob Schleiden and Theodor Schwann identified that cells were the fundamental unit of organization of all living things. The study of small structures involved passing light through them, and the microtome was invented to provide sufficiently thin slices of tissue to examine. Staining techniques using artificial dyes were established to help distinguish between different tissue types. Advances in the fields of histology and cytology began in the late 19th century along with advances in surgical techniques allowing for the painless and safe removal of biopsy specimens. The invention of the electron microscope brought a significant advance in resolution power and allowed research into the ultrastructure of cells and the organelles and other structures within them. About the same time, in the 1950s, the use of X-ray diffraction for studying the crystal structures of proteins, nucleic acids, and other biological molecules gave rise to a new field of molecular anatomy. Equally important advances have occurred in non-invasive techniques for examining the body's interior structures.
==== Elimination ==== MDMA and metabolites are primarily excreted as conjugates, such as sulfates and glucuronides. MDMA is a chiral compound and has been almost exclusively administered as a racemate. However, the two enantiomers have been shown to exhibit different kinetics. The disposition of MDMA may also be stereoselective, with the S-enantiomer having a shorter elimination half-life and greater excretion than the R-enantiomer. Evidence suggests that the area under the blood plasma concentration versus time curve (AUC) was two to four times higher for the (R)-enantiomer than the (S)-enantiomer after a 40 mg oral dose in human volunteers. Likewise, the plasma half-life of (R)-MDMA was significantly longer than that of the (S)-enantiomer (5.8 ± 2.2 hours vs 3.6 ± 0.9 hours). However, because MDMA excretion and metabolism have nonlinear kinetics, the half-lives would be higher at more typical doses (100 mg is sometimes considered a typical dose).
Sources: en.wikipedia.org
Absolute bioavailability compares the bioavailability of the active drug in systemic circulation following non-intravenous administration (i.e., after oral, buccal, ocular, nasal, rectal, transdermal, subcutaneous, or sublingual administration), with the bioavailability of the same drug following intravenous administration. It is the fraction of exposure to a drug (AUC) through non-intravenous administration compared with the corresponding intravenous administration of the same drug. The comparison must be dose normalized (e.g., account for different doses or varying weights of the subjects); consequently, the amount absorbed is corrected by dividing the corresponding dose administered. In pharmacology, in order to determine absolute bioavailability of a drug, a pharmacokinetic study must be done to obtain a plasma drug concentration vs time plot for the drug after both intravenous (iv) and extravascular (non-intravenous, i.e., oral) administration. The absolute bioavailability is the dose-corrected area under curve (AUC) non-intravenous divided by AUC intravenous. The formula for calculating the absolute bioavailability, F, of a drug administered orally (po) is given below (where D is dose administered).
Cefuroxime axetil, sold under the brand name Ceftin among others, is a second generation oral cephalosporin antibiotic. It is an acetoxyethyl ester prodrug of cefuroxime which is effective orally. The activity depends on in vivo hydrolysis and release of cefuroxime tablets. It was patented in 1976 and approved for medical use in 1987.
Medium-velocity: Between 360 m/s (1,200 ft/s) and 600 m/s (2,000 ft/s) These are more typical of shotgun blasts or higher caliber handguns like magnums. The risk of infection from these types of wounds can vary depending on the type and pattern of bullets fired as well as the distance from the firearm.
The concept of a "Fortress North America" emerged during the Second World War and persisted into the Cold War to refer to the option of defending Canada and the United States against their enemies if the rest of the world were lost to them. This option was rejected with the formation of NATO and the decision to permanently station troops in Europe. In the summer of 1951, Project Vista started, in which project analysts such as Robert F. Christy looked at how to defend Western Europe from a Soviet invasion. The emerging development of tactical nuclear weapons was looked upon as a means to give Western forces a qualitative advantage over the Soviet numerical supremacy in conventional weapons. Several scares about the increasing ability of the Soviet Union's strategic bomber forces surfaced during the 1950s. The defensive response by the United States was to deploy a fairly strong "layered defense" consisting of interceptor aircraft and anti-aircraft missiles, like the Nike, and guns, like the M51 Skysweeper, near larger cities. However, this was a small response compared to the construction of a huge fleet of nuclear bombers. The principal nuclear strategy was to massively penetrate the Soviet Union. Because such a large area could not be defended against this overwhelming attack in any credible way, the Soviet Union would lose any exchange. This logic became ingrained in American nuclear doctrine and persisted for much of the duration of the Cold War.
During the period when Germany was divided, the Lower Saxon border crossing at Helmstedt found itself on the main transport artery to West Berlin and, from 1945 to 1990 was the busiest European border crossing point. Of economic significance for the state was the Volkswagen concern, that restarted the production of civilian vehicles in 1945, initially under British management, and in 1949 transferred into the ownership of the newly founded country of West Germany and state of Lower Saxony. Overall, Lower Saxony, with its large tracts of rural countryside and few urban centres, was one of the industrially weaker regions of the federal republic for a long time. In 1960, 20% of the working population worked on the land. In the rest of the federal territory the figure was just 14%. Even in economically prosperous times the jobless totals in Lower Saxony are constantly higher than the federal average. In 1961 Georg Diederichs took office as the minister president of Lower Saxony as the successor to Hinrich Wilhelm Kopf. He was replaced in 1970 by Alfred Kubel. The arguments about the Gorleben Nuclear Waste Repository, that began during the time in office of minister president Ernst Albrecht (1976–1990), have played an important role in state and federal politics since the end of the 1970s. In 1990 Gerhard Schröder entered the office of minister-president. On 1 June 1993, the new Lower Saxon constitution entered force, replacing the "Provisional Lower Saxon Constitution" of 1951.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.
It contains the 4-7 fragment of adrenocorticotropic hormone extended at the C terminus. That truncation removes the region associated with steroidogenic activity. The design intent was to keep neurotrophic properties while avoiding full hormonal effects.
No natural source of the intact heptapeptide is known. It is produced by solid-phase peptide synthesis. Some related ACTH fragments arise as hormone processing products, but the Pro-Gly-Pro extension is a designed addition rather than a natural sequence.
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.